Funding
ONCOLOGY
This study was funded by grants from the National Key Research and Development Program of China (2022YFC2505800), Chinese Society of Clinical Oncology (CSCO)-Hengrui Clinical Oncology Research Fund (No:Y-HR2017-046), the National Natural Science Foundation of China (No. 81425018, No. 81672868, No. 81802775, No. 82073003, No. 82002852, No. 82003267, No. 81803105, No. 82222050), Postdoctoral Innovative Talent Support Program (BX20220361), the Sci-Tech Project Foundation of Guangzhou City (201707020039), the Sun Yat-sen University Clinical Research 5010 Program (No. 2016010, No. 201315, No. 2015021, No. 2017010, No. 2016013, No. 2019023), Innovative research team of high-level local universities in Shanghai (SSMU-ZLCX20180500), the Natural Science Foundation of Guangdong Province (No. 2017A030312003, No. 2018A0303131004), the Natural Science Foundation of Guangdong Province for Distinguished Young Scholar (No. 2018B030306001), the Health & Medical Collaborative Innovation Project of Guangzhou City (No. 201803040003), Pearl River S&T Nova Program of Guangzhou (No. 201806010135), the Planned Science and Technology Project of Guangdong Province (2019B020230002), the Key Youth Teacher Cultivating Program of Sun Yat-sen University (20ykzd24), and the Fundamental Research Funds for the Central Universities.